Avid Radiopharmaceuticals, Inc. Receives 2007 Frost & Sullivan Molecular Imaging Technology Innovation of the Year Award

PHILADELPHIA--(BUSINESS WIRE)--Avid Radiopharmaceuticals, Inc., a product-focused molecular imaging company, has received Frost & Sullivan’s 2007 North American Molecular Imaging Technology Innovation of the Year Award. The Award recognizes Avid’s innovative contributions to the molecular imaging industry, including its commitment to improve the detection and diagnosis of Alzheimer’s disease (AD). Avid has taken a leading role in the research and development of novel compounds for positron emission tomography (PET) imaging of amyloid plaques in the brain, which may allow earlier diagnosis and enable more effective treatment plans for patients with suspected AD.

Back to news